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Kathleen M. Giacomini6,7, Yen-Jen Oyang1, Chien-Yu Chen2,4* and for the Alzheimer’s Disease Neuroimaging
InitiativeAbstract
Background: Genome-wide association studies (GWAS) provide a powerful means to identify associations between
genetic variants and phenotypes. However, GWAS techniques for detecting epistasis, the interactions between
genetic variants associated with phenotypes, are still limited. We believe that developing an efficient and effective
GWAS method to detect epistasis will be a key for discovering sophisticated pathogenesis, which is especially
important for complex diseases such as Alzheimer’s disease (AD).
Results: In this regard, this study presents GenEpi, a computational package to uncover epistasis associated with
phenotypes by the proposed machine learning approach. GenEpi identifies both within-gene and cross-gene
epistasis through a two-stage modeling workflow. In both stages, GenEpi adopts two-element combinatorial
encoding when producing features and constructs the prediction models by L1-regularized regression with stability
selection. The simulated data showed that GenEpi outperforms other widely-used methods on detecting the
ground-truth epistasis. As real data is concerned, this study uses AD as an example to reveal the capability of
GenEpi in finding disease-related variants and variant interactions that show both biological meanings and
predictive power.
Conclusions: The results on simulation data and AD demonstrated that GenEpi has the ability to detect the
epistasis associated with phenotypes effectively and efficiently. The released package can be generalized to largely
facilitate the studies of many complex diseases in the near future.
Keywords: GWAS, Epistasis, Machine learningBackground
Genome-wide association studies (GWAS) is a univari-
ate examination of a genome-wide set of genetic variants
to determine if any single variant is associated with the
phenotype of interest [1]. The first GWAS was published
in 2002 [2], and 3 years later, the most remarkable
GWAS regarding age-related macular degeneration© The Author(s). 2020 Open Access This artic
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Full list of author information is available at the end of the article(AMD) was published [3]. Their study investigated the
association of 105,980 single nucleotide polymorphisms
(SNPs) with AMD on 96 cases and 50 control subjects.
This study showed that the SNPs in the complement
factor H (CFH) gene, including a non-synonymous SNP,
are significantly associated with AMD. Up to 2019, there
have been more than hundreds of thousands individuals
being studied in typical GWAS protocols, and over 210,
498 variant-disease associations between 117,337 SNPs
and 10,358 phenotypes have been discovered [4]. These
studies demonstrated the potential of GWAS to identify
genetic variants associated with many categories of phe-
notypes, including risks for diseases such as various can-
cers, and variations in therapeutic and adverse responses
to drugs. However, the success of univariate GWAS is
limited to monogenic phenotypes (e.g. Mendelianle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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as epistasis on the formation of diseases [5] is often
underestimated in traditional GWAS analysis [6–8].
A major limitation of traditional GWAS is that it con-
siders only one genetic variant at a time, and ignores
underlying epistasis of variants that might have stronger
associations [9]. Researchers have found that GWAS has
limitation in identifying the association in complex dis-
eases [10, 11]. Easton et al. suggested that a number of
susceptible loci identified by GWAS usually have very
small effect sizes [12]. Studies have also demonstrated
that the existence of epistasis is an important factor con-
tributing to phenotypes, especially in complex diseases
such as hypertension, diabetes and obesity [11]. There-
fore, developing analytical methods to identify epistasis
efficiently is critical to understanding the genetic factors
[8, 13], and has attracted a wide range of research inter-
ests in recent years [7, 14].
There are, however, two main challenges to discover epis-
tasis: computational complexity and statistical power [15].
The first challenge results from the curse of dimensionality.
When more genetic variants are considered, the number of
interactions increases exponentially. Based on the specifica-
tion of a major commercial technology, Illumina Arrays, a
whole-genome array can investigate over 4 million markers
per sample simultaneously. In order to evaluate the pair-
wise interactions from this microarray, about 8 × 1012 stat-
istical tests need to be processed. Even though Marchini
et al. have demonstrated that pairwise interactions of 3 ×
105 loci is computationally possible with currently available
computational resources, it still remains challenging when
the Illumina Arrays are considered [16]. The second chal-
lenge is the issue of statistical power. Since a huge number
of statistical tests are conducted on a limited sample size
with high-dimensional interactions, many false positives
arise by random chances. In recent years, new methods
have been developed to tackle the issue of epistasis [11, 17].
Statistical approaches include FastEpistasis [18] and
BOOST [19]; both of them has been included in a well-
known GWAS software called PLINK [20, 21]. Machine
learning approaches such as Multifactor Dimensionality Re-
duction [22], ReliefF [23], random forest-like algo-
rithms [24–26] and other methodologies have also been
developed for detecting epistasis [17].
Since the biological experiments used to validate these
methodologies are still in demand, there are no standard
analysis methods for epistasis despite the rapid improve-
ment in computational performance. In 2016, Murk used
FastEpistasis and BOOST to search SNP-SNP interactions
on a huge dataset called Genetic Epidemiology Research on
Adult Health and Aging (GERA) that included 78,486 sub-
jects, but still failed to detect a significant and replicable
interaction after exhaustively searching through 45 billion
possible interactions for 10 complex diseases of interest[27]. Alzheimer’s disease (AD) is one of the most important
complex diseases and its pathogenesis, which clearly has a
genetic basis, is still ill-defined. In 2014, Sage Bionetworks
held a competition called The Dialogue for Reverse Engin-
eering Assessments and Methods Challenge (DREAM Chal-
lenge) for AD, which tried to use crowdsourcing to assess
the capability of current computational methods to predict
the change in cognitive examination based on genetic data.
However, no significant contribution of genetic features ex-
cept the APOE haplotype to the predictive performance was
observed by any competition teams [28]. In order to dis-
cover more SNP interactions with both statistical and bio-
logical significance, this study presents GenEpi, a package to
reveal epistasis related to the phenotype using machine
learning and introduces the application of GenEpi on AD.
Implementation
The architecture of GenEpi is shown in Fig. 1. GenEpi is
designed to group SNPs by a set of loci in the gnome. For
examples, a locus could be a gene. In other words, we use
gene boundaries to group SNPs. A locus can be generalized
to any particular regions in the genome, e.g. promoters, en-
hancers, etc. GenEpi first considers the genetic variants
within a particular region as features in the first stage, be-
cause it is believed that SNPs within a functional region
might have a higher chance to interact with each other and
to influence molecular functions. The idea of within-gene
epistasis analysis followed by cross-gene analysis is not new,
which has also been used in previous studies [29–32]. Dif-
ferently, GenEpi adopts two-element combinatorial encod-
ing when producing features and models them by L1-
regularized regression with stability selection, which will be
explained in Section 2.3. In the first stage (STAGE 1) of
GenEpi, the genotype features from each single gene will be
combinatorically encoded and modeled independently by
L1-regularized regression with stability selection. In this
way, we can estimate the prediction performance of each
gene and detect within-gene epistasis with a low false posi-
tive rate. In the second stage (STAGE 2), both of the indi-
vidual SNP and the within-gene epistasis features selected
by STAGE 1 are pooled together to generate cross-gene
epistasis features, and modeled again by L1-regularized re-
gression with stability selection as STAGE 1. Finally, the
user can combine the selected genetic features with envir-
onmental factors such as clinical features to build the final
prediction models. In addition to the main procedures, two
pre-processing steps are also implemented in GenEpi: re-
trieving the gene information from public databases and re-
ducing the gene information from public databases and
reducing the dimensionality of the features using linkage
disequilibrium (LD). In the end, we released a Python pack-
age that implements GenEpi. The details of these steps and
the GenEpi method will be described in the following
sections.
Fig. 1 The architecture of GenEpi
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To obtain the gene information such as official gene sym-
bols and genomic coordinates, we retrieved kgXref and
knownGene data table from the UCSC human genome an-
notation database [33, 34]. The version of the database we
used is the Feb. 2009 assembly of the human genome hg19,
GRCh37 Genome Reference Consortium Human Reference
37. The two data tables were merged in order to generate a
local database containing the gene symbols as well as the
genomic coordinates of each gene. The in-house script we
built could update this local database automatically. It is
noted that there are many different categories of genes in
the RefSeq database. In this study, we only focused on the
mRNA and non-coding RNA (22,376 genes in total). Theselected transcripts were projected on the genomic coordi-
nates and the coordinates of corresponding genes were de-
termined based on the leftmost and rightmost positions of
the corresponding transcripts. Moreover, to discover the
factors that might affect the transcription of genes, we also
retained the promoter region of each gene. In genetics, the
promoter region is a segment of DNA that initiates the tran-
scription of a particular gene. Promoters are located near
the transcription start sites of genes, on the upstream of the
same DNA strand (towards the 5′ region of the sense strand
of the transcript). In general, a promoter region can be 100–
1000 base pairs long. In this study, we extracted 1000 nucle-
otides on the upstream of the starting position of each gene
as the promoter region.
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In GWAS datasets, a SNP often exhibits high depend-
ency with its nearby SNPs because of linkage disequilib-
rium (LD). In the practical implantation, we prefer to
group these dependent features to reduce the dimension
of features. In other words, we can take the advantages
of LD to reduce the dimensionality of SNP features. In
this regard, we adopted the same approach developed by
Lewontin [35] to estimate LD (see Additional file 1
Section S.1). We used D’ > 0.9 and r2 > 0.9 as the criteria
to group highly dependent SNP features as blocks. In each
block, we chose the features with the largest minor allele
frequency to represent other features in the same block. It
is important to look at the SNPs falling in the same LD
blocks with the SNPs discovered by GenEpi. Some true in-
teractions might be skipped owing to some strong signals
provided by the SNPs in the same LD block.
Discovery of within-gene epistasis
The main objective of the first stage in GenEpi is to se-
lect candidate features from each gene. In order to ex-
tract SNP features for a gene, we used the start and end
positions of each gene from the local UCSC database to
split the SNP features after dimension reduction. Since
there are 22,376 genes in the UCSC database, we ob-
tained 22,376 subsets of the SNP features. In each sub-
set, a SNP feature with the alleles ‘A’ and ‘a’ could have
three possible genotypes, AA, Aa and aa, which are used
to refer to the pairs of alleles. The pairs of alleles are
subsequently separated into three binary features using
one-hot encoding. In order to evaluate epistasis, we gen-
erated interacting features by crossing each pair of geno-
type features. Considering the false positive rate and
computational complexity, we only focused on pairwise
interactions of epistasis throughout this study. We de-
fined the interaction between two SNPs in Eq. 1. In Eq.
1, α1SNP1 + α2SNP2 stand for the additive interactions
and αint(1,2) SNP1⊗ SNP2 represents the synergistic in-
teractions that contain nine terms.
y ¼ α0 þ
X
m∈ AA;Aa;aaf g
α1;mSNP1;m
þ
X
m∈ AA;Aa;aaf g
α2;mSNP2;m
þ
X
m;n∈ AA;Aa;aaf g
α1;m;2;nSNP1;mSNP2;n
¼ α0 þ α1SNP1 þ α2SNP2 þ α int 1;2ð ÞSNP1  SNP2
ð1Þ
Before modeling each subset of genotype features, two
criteria were adopted to exclude low quality data. Thefirst criterion is that the genotype frequency of a feature
should exceed 5%, where the genotype frequency means
the proportion of a genotype among the total samples in
the dataset. The second criterion is regarding the associ-
ation between the feature and the phenotype. We used
χ2 test to estimate the association between the feature
and the phenotype, and the p-value should be smaller
than 0.01. In the end, a gene may have multiple SNPs.
The general form of the linear model for a gene with k
SNPs is defined as Eq. 2, which is termed as two-
element combinatorial encoding.
y ¼ α0 þ
Xk
i¼1
αiSNPi
þ
Xk
i¼1
Xk
j¼1∩ j≠i
α int i; jð ÞSNPi⨂SNP j ð2Þ
We conducted L1-regularized regression [36] with sta-
bility selection [37] for modeling each gene. The sparsity
of the L1-regularized model prefers solutions with a
smaller number of features, which effectively reduces the
number of features. As in Equation 3, L1-regularized re-
gression uses an additional regularization term λ‖α‖1 to
restrict the weight of each feature by shrinking some of
them to 0 so that the non-zero remainders can represent
the exact set of true features when given a proper λ. In
Equation 3, we have the vector SNP = (SNP1, …, SNPi,
…, SNPk, SNP1⊗ SNP2, …, SNPi⊗ SNPj, …, SNPk-1⊗
SNPk), the corresponding coefficients α = (α1, …, αi, …,
αk, αint(1,2), …, αint(i,j), …, αint(k-1, k)), the target yl takes
the values {− 1, 1} at sample l and c is a constant to be
determined during modeling.
α^λ¼ min
α;c
Xn
l¼1
log exp −yl  SNPTl αþc
  þ1 þλ αk k1
ð3Þ
, where n stands for the number of samples. It should be
noticed that, if the features are conditional dependent,
the solution of these equations will not be unique. It
would lose generality to determine the proper amount of
λ when we only consider a possible solution of weight
vector α. Resampling is an intuitive technique to in-
crease the generality, which can largely reduce the false
positive rate. Here, we used stability selection [37] to
tackle this problem. Stability selection works by resam-
pling and remodeling the training set hundreds of times,
followed by picking out the features that are repeatedly
selected across randomization. In this study, we exe-
cuted this randomization 500 times, and the features se-
lected by stability selection would be retained for the
next stage.
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In the second stage, we used the features selected by
STAGE 1 to generate cross-gene epistasis features. To
avoid missing any possible association between genotype
features and phenotype. In the default setting of the
GenEpi package, we include all the genes with non-zero
F1 score to go into the next stage. Then we applied the
same selection procedure described in Section 2.3 to find
the cross-gene epistasis that are associated with the
phenotype. The procedures were slightly modified here.
Since we only focused on pairwise interactions, instead
of using the entire features we selected in STAGE 1, we
only used single-SNP features to generate cross-gene
epistasis features. Also, we used the genotype frequency
and the p-values of χ2 test to control the quality of fea-
tures and to avoid overfitting. Nevertheless, the p-value
of each feature in this stage should be smaller than 10− 5.
All of the features from different genes would be merged
for modeling cross-gene epistasis. We conducted L1-
regularized regression for modeling, and the stability se-
lection were used once again to select the final genotype
feature set. Since the phenotype may also be affected by
environmental factors, after determining the final set of
genotype features, the user can included the environ-
mental factors such as clinical assessments for construct-
ing the final model. Subsequently, the final model was
evaluated through a process called double cross valid-
ation (CV). In the external loop of double CV, all the in-
stances were divided into two subsets to serve as
training and independent test sets. In this study, we used
2-fold CV and leave-one-out CV (LOO CV) in external
loop for evaluation. In the internal loop, we also used 2-
fold CV for model selection.
Materials
This study applied GenEpi on an AD cohort, which was
used in Alzheimer’s disease Dream Challenge [28], In
total, the cohort consists of 767 participants, who were
healthy elderly, mild cognitive impairment (MCI) and
AD patients from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) database. The 767 ADNI participants
consist of 241 cognitively normal (CN), 130 Early MCI
(EMCI), 273 Late MCI (LMCI) and 123 AD participants.
According to the definition of the four categories used
in the ADNI database, the samples of AD are in same
stage. We adopted only genetic features in this study. All
the genetic data has been pre-processed by the orga-
nizers that held the challenge [28]. The genetic data
were genotyped using the Illumina Human610-Quad
BeadChip and Illumina HumanOmniExpress BeadChip.
The multidimensional scaling analysis was applied by
PLINK using HAPMAP3 to ensure that samples are
within the cluster of European populations. Subse-
quently, the data were imputed according to the 1000genome haplotypes. After imputation, there were 12,809,
667 genotype features in total. For predicting the diag-
nosis of AD, we used 364 participants, of which the clin-
ical diagnosis are CN or AD, to predict which samples
are control subjects or the AD patients.Results
This study compared GenEpi with several commonly
used algorithms for detecting epistasis, including FastE-
pistasis, BOOST and ReliefF. The simulation data dem-
onstrated that GenEpi outperforms the other methods in
ranking the true epistasis as the top one. As real data is
concerned, the results suggest that the epistasis selected
by GenEpi has the best predictive power for diagnosis of
AD. The proposed model of predicting AD contains 14
genetic features, including 24 SNPs from 12 genes that
contain the well-known causal gene, APOE. The 2-fold
cross validation (CV) and leave-one-out CV (LOO CV)
accuracy of this model are 0.829 and 0.832, respectively.
The results on AD demonstrated that GenEpi has the
ability to detect the epistasis associated with the pheno-
type effectively and efficiently. The released package can
be generalized to largely facilitate the studies of many
complex diseases in the near future.
We will demonstrate our experiments in following
three parts of this section. In the first part, we applied
GenEpi and other algorithms for detecting epistasis, in-
cluding FastEpistasis [18], BOOST [19] and ReliefF [23,
38] on simulation data for validation and comparison. In
the second part, we applied GenEpi on the ADNI dataset
to categorize each sample as control subjects or AD pa-
tients, evaluated by precision, recall, accuracy and F1
score (2 × (precision × recall) / (precision + recall)). In
the final part, we compared GenEpi with other algo-
rithms on the ADNI dataset in terms of computing time
and prediction performance on real data.Experiments on simulation data
We applied different algorithms on simulation data for
validation and comparison. All of the simulation datasets
are generated by the simulator GAMETES [39], which is
publicly accessible on the web site https://popmodels.
cancercontrol.cancer.gov/gsr/packages/gametes/. We de-
signed two types of simulation datasets: basic and com-
plex models. The ‘Model 1’, ‘Model 2’ and ‘Model 3’ are
simulation datasets with the basic model, which means
that each dataset contained only one epistasis consisting
of a SNP pair. All of the basic-model datasets are in the
same setting as follows: #individuals = 2000, case/control
ratio = 1, #SNPs = 100, #replicates = 100, minor allele fre-
quency of target SNPs = 0.2, and heritability = 0.2. The
complex model means one dataset contains multiple
epistasis from different SNP pairs. Here, the ‘Combined
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three epistasis from the previous three basic models.
Figure 2 provided the results of these four simulation
datasets. Figure 2a shows that the ranking of the target epis-
tasis reported by GenEpi in the 100 replicates of each basic-
model dataset are always ranked as the first. In contrast, for
FastEpistasis and BOOST, the medians of the ranking of the
target epistasis among the 100 runs of simulation are one
but the averages are not. The number of failures of FastEpis-
tasis and BOOST in 100 replicates of three basic models are
6, 1, 16 and 5, 1, 14, respectively. For the result of the com-
plex model dataset in Fig. 2b, the superiority of GenEpi over
other algorithms is more obvious. In the 100 runs of simula-
tion, GenEpi reported the three target epistasis as the top
three important features every time. In contrast, FastEpista-
sis and Boost failed to report the three target epistasis as the
top three important features consistently.
When ReliefF was compared, since the Python package
scikit-rebate [38] that we used for implementing ReliefF
only reports the importance of individual SNPs instead
of the scores for epistasis (SNP pairs), we listed the me-
dians of ReliefF’s ranking for each SNP in the target
epistasis in Table 1. Table 1 reveals that ReliefF can de-
tect the SNPs in the target epistasis in the basic models,Fig. 2 The boxplot for the rank of the target epistasis in different algorithm
consisting of a SNP pair. b The result of the complex-model dataset, which
SNP 1 and SNP 2 and so on. The values on the boxplot are the medians ofbut failed to report the three target epistasis as the top
three important features in the complex model dataset.
The superiority of GenEpi is owing to the proposed
two-element combinatorial encoding of the genotype fea-
tures and the L1-regularized regression with stability se-
lection. In contrast with other statistical algorithms such
as FastEpisasis and BOOST, which only evaluate the epis-
tasis of a SNP pair one at a time, GenEpi considers inter-
actions between combinatorial features by multivariate
models. Moreover, the false positives among the epistasis
can be filtered out by resampling and remodeling the
dataset hundreds of times. To evaluate the effect of stabil-
ity selection, we applied both L1-regularized regression
with and without stability selection on the complex model
dataset to compare the number of false positives, which is
defined as the number of non-target epistasis in the final
output of GenEpi. As shown in Fig. 3, stability selection
can reduce the mean false positive rate effectively and
minimize the variance of false positive rate as well.
Classifying AD patients
In predicting control subjects or AD patients, we applied
GenEpi on the 364 samples with CN (as control) or AD.
After dimensionality reduction, 12,102,888 out of the 12,s. a The results of three basic-model datasets with one epistasis
contained three epistasis. The ‘S1-S2’ means the epistasis between
the rank of the target epistasis among the 100 runs of simulation
Table 1 The medians of the rank of the SNPs in the target
epistasis for ReliefF
SNP 1 SNP 2 SNP 3 SNP 4 SNP 5 SNP 6
Basic Model 1 2 1 2 1 2
Complex Model 7 8.5 9.5 11.5 11 19.5
Table 2 The score of different models in predicting control
subjects or AD patients
Precision Recall F1 Score Accuracy
Training 0.9633 0.8537 0.9052 0.9396
2-fold CV 0.7748 0.6992 0.7350 0.8297
LOO CV 0.8100 0.6585 0.7265 0.8324
F1 Score = 2 × (Precision × Recall) / (Precision + Recall); ‘Training’ stands for the
process of a single-loop CV; ‘2-fold CV’ means that 2-fold CV was used in the
external loop of double CV; ‘LOO CV’ means that LOO CV was used in the
external loop of double CV
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916,249 of them are located in 20,206 genes (Additional
file 1 Table S1). In the step 4 of selecting epistasis, there
are 34,689 genetic features selected and 765 of them are
single SNP features, while the other 33,924 are epistasis
features within genes. The final model contained 14 gen-
etic features, including 24 SNPs from 12 genes. These
features contained two single SNP features, 11 within-
gene epistasis features and one cross-gene epistasis fea-
ture. As shown in Table 2, the 2-fold cross validation
(CV) and leave-one-out CV (LOO CV) accuracy of this
model are 0.83 and 0.83, respectively.
We listed the statistical significance of the selected
genetic features in Table 3. The first column lists each
feature by its RSID (Reference SNP cluster ID) and the
genotype (denoted as RSID_genotype), the pairwise epis-
tasis features are represented using two SNPs. The last
column describes the genes where the SNPs are located
according to the genomic coordinates. We used a star
sign to denote the epistasis between genes. Here, only
the feature (rs3130614_BB, rs41276317_AB) is cross-
gene epistasis (for MICB and TOB2). The weights in the
second column were extracted from the linear model we
defined in Section 2.4. The signs of the weights indicate
if a feature is a causal or protective genotype, which is
consistent with the corresponding odds ratio. The p-
value of the χ2 test showed that these features are signifi-
cantly associated with the phenotype.
Comparison with different algorithms
In this section, we compared GenEpi with other algo-
rithms for detecting epistasis, including FastEpistasis
[18], BOOST [19] and ReliefF [23] in terms of comput-
ing time and prediction performance. We used Micro-
soft Azure E32 v3 as the computing resource, whichFig. 3 The boxplot of false positives in L1-regularized regression with andcontains 32 CPUs and 256 GB RAM. Since the PLINK
(version 2.0) has imported FastEpistasis and BOOST, we
used PLINK to test these two algorithms. For ReliefF, we
employed a Python package called scikit-rebate [38] for
implementation. Among these algorithms, only FastEpis-
tasis can afford the computation of the whole set of
SNPs. In this regard, 12,809,667 SNPs were used by Fas-
tEpistasis (Table 4). On the other hand, GenEpi only fo-
cuses on the SNPs in the gene regions. In this regard,
the number of input SNPs for estimating epistasis re-
duced to 4,916,249. BOOST took the same subsets of
SNPs as GenEpi (Table 4). When taking the same subset
of SNPs as GenEpi and BOOST, ReliefF still caused
memory errors. Therefore, we used the subsets of SNPs
that selected by STAGE 1 of GenEpi as the input of
ReliefF, which are 33,868. We selected the top 15, 30, 45
and 60 rankings from the results of these algorithms for
comparing the prediction performance, and used L1-
regularized regression to build the models for classifying
AD patients for comparison. Table 4 shows that GenEpi
is an efficient method, which can deliver satisfied results
for the epistasis discovery of 4 millions of SNPs within
9.95 CPU-days. The comparison of execution time is un-
fair to FastEpistasis, since FastEpistasis used the whole
set of SNP, which is about 2.6 time larger than the sub-
set of it be used in GenEpi. When accuracy is consid-
ered, GenEpi has the best prediction performance
despite the fact that GenEpi only uses the subset of
SNPs from the final model. GenEpi shows that the time
needed for identifying epistasis can be drastically re-
duced, without compromise to the performance. Wewithout stability selection
Table 3 The statistical significance of genetic features selected by GenEpi in predicting patients with AD
Selected SNPs (RSID) Weight Odds Ratio χ2-test
P-value
Genotype
Frequency
Gene
rs3130614_BB, rs41276317_AB 3.16 19.23 1.42E-09 0.0742 MICBaTOB2
rs12095538_BB, rs2774308_AB 2.41 7.69 6.87E-07 0.0824 SYT6
rs12926153_AB, rs12922908_AA 1.18 4.83 6.89E-07 0.1511 CLEC16A
rs9652600_AB, rs12922908_AA 0.94 4.83 6.89E-07 0.1511 CLEC16A
rs9344977_BB, rs56148686_AB 1.94 4.32 1.14E-06 0.1813 BACH2
rs429358_AA −2.01 0.17 1.73E-06 0.5962 APOE
rs56233035_AB, rs3678_AB 2.26 10.16 1.91E-06 0.0604 CACNA1E
rs11675339_AA, rs2710687_AA 2.32 3.94 3.55E-06 0.1923 VSNL1
rs12189429_BB, rs6881360_AA 1.36 4.34 3.65E-06 0.467 ADAMTS12
rs12187423_BB, rs6881360_AA 0.58 4.34 3.65E-06 0.467 ADAMTS12
rs10831829_BB, rs12366151_AA 3.48 9.50 4.90E-06 0.0577 PARVA
rs2052573_BB, rs34580133_AB 1.80 4.08 5.00E-06 0.1648 LINC00299
rs2421701_AB, rs200512701_AB 1.82 4.12 5.29E-06 0.1593 TNKS2
rs769449_AA −1.19 0.16 8.42E-06 0.6648 APOE
The sign ‘a’ between two gene symbols indicates cross-gene epistasis
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Fig. 4, and it shows that GenEpi achieved the best per-
formance in double 2-fold CV procedures, of which the
area under the curve (AUC) is 0.85.Discussion
The results in the previous section revealed the power of
GenEpi to identify phenotype-associated epistasis effi-
ciently. GenEpi selected 14 features from 12 genes to
categorize patients with AD. Since AD is a chronic neu-
rodegenerative disease, our findings would be supported
if the gene identified by GenEpi are expressed in brains.
We downloaded the median RPKM by tissue dataset
(GTEx Analysis V6: dbGaP Accession phs000424.v6.p1)
of the GTEx Project [40] and plotted a heatmap to in-
spect the gene expression of these genes in different tis-
sues, as shown in Fig. 5. Among the 12 genes selected by
GenEpi, 11 have high expression level in the brain tis-
sues. In addition, five genes, CLEC16A, VSNL1, SYT6,
CACNA1E and LINC00299, have a similar expression
pattern with APOE. The R script for drawing the heat-
map for GTEx dataset could be found in Additional file 2.Table 4 The comparison of different algorithms
Algorithm # Input SNP Time Cost Top 15 Top 30 Top 45 Top 60
GenEpi 4,916,249 9.95 0.76 0.72 0.71 0.68
BOOST 4,916,249 2157.6 0.31 0.24 0.30 0.37
ReliefF 33,868 0.11 0.52 0.48 0.45 0.46
FastEpistasis 12,809,667 836.8 0.62 0.61 0.60 0.59
‘Time Cost’ is the time spent on identifying the epistasis, which was measured
by single CPU time in days. The values in column top 15, top 30, top 45 and
top 60 are the 2-fold CV scores. The 2-fold CV scores are the F1 scoresThese 12 genes are categorized as cross-gene epistasis,
single-gene epistasis and single-SNP features based on
the feature types selected by GenEpi. GenEpi detected
only one cross-gene epistasis, which is MICB * TOB2.
We found several evidences to demonstrate that this
interaction might have true association with AD (see
Additional file 1 Section S.2.1).
About the 11 single-gene epistasis, there are several
possible reasons accounting for intramolecular SNP-SNP
interactions identified in this study. The first is a syner-
gistic regulation of transcription [41], the second is a
synergistic interaction between transcriptional and post-
transcriptional regulation [42], and the third is an intra-
molecular SNP pair modulating the expression of two
separate neighboring genes [43]. Most of the single-gene
epistasis selected by GenEpi can be explained by these
three possible reasons (see Additional file 1 Section
S.2.2) and only two of the SNP-SNP interactions are not
immediately clear at this moment. Last, there are only
two single-SNP features and both of them are located in
APOE, which is a well-known causal gene of AD, reveal-
ing that GenEpi is an effective tool to identify disease-
causing genes. Moreover, GenEpi successfully selected
out the SNP rs429358, which determines the allele type
of APOE with rs7412.
While GenEpi has shown its ability to identify epistasis
efficiently, it might still has the following limitations.
Firstly, GenEpi can only detect pairwise interactions.
Considering the false positive rate and computational
complexity, it may not be appropriate for continuously
generating the high-dimension interactions. A feature
engineering-free method such as deep learning could be
applied for discovering the high-dimension interactions.
Fig. 4 The ROC curves of different algorithms
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might cause memory errors when calculating the epista-
sis of a gene containing a large number of SNPs. We
recommend that the memory for running GenEpi should
be over 256 GB. Since most of features may not be asso-
ciated with the phenotype, additional filters for feature
selection can be designed to further reduce the number
of features before modeling. Finally, a small sample size
may lead overfitting, which forces us to use strict thresh-
olds during feature selection. In this way, GenEpi de-
livers a high precision rate, but might suffer having falsenegatives. This implies different GWAS data might detect
different sets of true positives. In traditional GWAS, meta-
analysis [44] can be used to identify the common effects
from multiple studies. This post statistical procedure could
be considered for obtaining a common set from multiple
GWAS data. In summary, the results of this study demon-
strated that GenEpi is a promising software package to
identify causal SNPs and epistasis in GWAS, and it can be
further used to predict the phenotypes. With the demon-
strated efficiency, GenEpi is a powerful tool to explore
gene-gene interactions that underlie complex diseases.
Fig. 5 The heatmap of gene expression in different tissues for the 12 genes selected by GenEpi. The blue box highlights the sub-regions of brain
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This study presents GenEpi, a computational package to
uncover epistasis associated with phenotypes by the pro-
posed machine learning approach, which adopts two-
element combinatorial encoding when producing features
and constructs the prediction models by L1-regularized re-
gression with stability selection. The results on simulation
data and AD demonstrated that GenEpi has the ability todetect the epistasis associated with phenotypes effectively
and efficiently. Furthermore, the release package GenEpi is
an open-source Python package and available free of charge
for non-commercial users. The package has been published
on The Python Package Index, and GitHub (https://github.
com/Chester75321/GenEpi), can be generalized to largely
facilitate the studies of many complex diseases in the near
future.
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Project name: GenEpi.
Project home page: https://github.com/Chester75321/
GenEpi
Operating system(s): Platform independent.
Programming language: Python.
License: MIT license.
Any restrictions to use by non-academics: license
needed.Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12859-020-3368-2.
Additional file 1. Supplementary information for literature survey of the
genetic features selected by GenEpi and the formulas for linkage
disequilibrium estimation.
Additional file 2. The R script to draw a heatmap for GTEx dataset.Abbreviations
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